Develops radiopharmaceuticals for central nervous system cancers.
Jun 2026Revenue $4.20M/yrExpenses $30.6M/yr
No trendCash runway ≈ 4 months from Jun 2026
Figures by year
When will Cerenome be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $4.20M and expenses $30.6M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $5.21M | $20.5M | −$15.3M |
| Dec 2024 | $5.82M | $20.5M | −$14.7M |
| Dec 2023 | $4.91M | $18.2M | −$13.3M |
| Dec 2018 | $3.67M | $12.4M | −$8.76M |
| Dec 2017 | $2.69M | $23.4M | −$20.7M |
| Dec 2016 | $4.66M | $24.4M | −$19.7M |
| Dec 2015 | $4.84M | $20.1M | −$15.3M |
| Dec 2014 | $4.95M | $37.4M | −$32.4M |
| Dec 2013 | $7.12M | $37.8M | −$30.7M |
| Dec 2012 | $8.71M | $37.1M | −$28.4M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.